Approval Package for:

APPLICATION NUMBER: 209501Orig1s000

Trade Name: Lyrica CR

Generic or Proper Name: Pregabalin extended-release tablets

Sponsor: Pfizer, Inc.

Approval Date: October 11, 2017

Indication: For the management of neuropathic pain associated with diabetic neuropathy (DPN) and postherpetic neuralgia (PHN).
### Reviews / Information Included in this NDA Review.

<table>
<thead>
<tr>
<th>Reviews / Information</th>
<th>Indicator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td>X</td>
</tr>
<tr>
<td>Other Action Letters</td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td>X</td>
</tr>
<tr>
<td>REMS</td>
<td></td>
</tr>
<tr>
<td>Summary Review</td>
<td>X</td>
</tr>
<tr>
<td>Officer/Employee List</td>
<td>X</td>
</tr>
<tr>
<td>Office Director Memo</td>
<td></td>
</tr>
<tr>
<td>Cross Discipline Team Leader Review</td>
<td></td>
</tr>
<tr>
<td>Clinical Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Product Quality Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Non-Clinical Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Statistical Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Clinical Microbiology / Virology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Clinical Pharmacology Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Other Reviews</td>
<td>X</td>
</tr>
<tr>
<td>Risk Assessment and Risk Mitigation Review(s)</td>
<td></td>
</tr>
<tr>
<td>Proprietary Name Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Administrative/Correspondence Document(s)</td>
<td>X</td>
</tr>
</tbody>
</table>
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

209501Orig1s000

APPROVAL LETTER
NDA 209501

Pfizer, Inc
235 East 42nd Street
New York, NY 10071

Attention: Mojgan Sadrarhami, PharmD
Senior Director, Worldwide Safety and Regulatory

Dear Dr. Sadrarhami:

Please refer to your New Drug Application (NDA) dated and received December 15, 2016, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for LYRICA CR (pregabalin) extended-release tablets, 82.5 mg, 165 mg, and 330 mg.

This new drug application provides for the use of LYRICA CR for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN).

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the prescribing information and Medication Guide). Information on submitting SPL files using eLIST may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As, available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible via publicly available labeling repositories.

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and immediate container labels that are identical to the enclosed carton and immediate container, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry
Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (May 2015, Revision 3). For administrative purposes, designate this submission “Final Printed Carton and Container Labels for approved NDA 209501.” Approval of this submission by FDA is not required before the labeling is used.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric studies requirement for this application because necessary studies are impossible or highly impracticable due to the very low prevalence of these conditions in the pediatric population.

POST-MARKETING AGREEMENT

We remind you of your general correspondence dated October 10, 2017, agreeing to the following post-marketing agreement:

Following approval of NDA 209501, the following dissolution data will be submitted in the next Annual Report:

- For release, dissolution data (at 1, 4, 9 and 24 hours) on all commercial scale batches of drug product manufactured.

- For stability, dissolution data (at 1, 4, 9 and 24 hours) on the first three commercial scale batches of drug product manufactured and annual production batches which will be selected at a rate of at least one batch per year per strength for stability testing per the protocol submitted in the post approval stability protocol and commitment section of NDA 209501 (section 3.2.P.8.2).

- Proposed dissolution acceptance criteria at each time point.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, the package insert, and Medication Guide to:
Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf).

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Shelly Kapoor, PharmD, Regulatory Project Manager, at (240) 402-2787.

Sincerely,

{See appended electronic signature page}

Ellen Fields, MD, MPH
Deputy Director
Division of Anesthesia, Analgesia, and Addiction Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosures:
  Content of Labeling
  Carton and Container Labeling

Reference ID: 4165845
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ELLEN W FIELDS
10/11/2017